Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $53
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Eva Fortea Verdejo maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $50 to $53.
Wells Fargo analyst Eva Fortea Verdejo maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $50 to $53.